Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
20.86
-2.14 (-9.30%)
At close: Oct 28, 2025, 4:00 PM EDT
21.35
+0.49 (2.35%)
After-hours: Oct 28, 2025, 7:01 PM EDT
Apollomics Revenue
In the year 2024, Apollomics had annual revenue of $198.00K, down -75.88%. Apollomics had revenue of $-1.57M in the half year ending December 31, 2024, with 477.21% growth.
Revenue (ttm)
$198.00K
Revenue Growth
-75.88%
P/S Ratio
107.46
Revenue / Employee
$15,231
Employees
13
Market Cap
44.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.00K | -623.00K | -75.88% |
| Dec 31, 2023 | 821.00K | 498.00K | 154.18% |
| Dec 31, 2022 | 323.00K | 321.00K | 16,050.00% |
| Dec 31, 2021 | 2.00K | -1.84M | -99.89% |
| Dec 31, 2020 | 1.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
APLM News
- 13 days ago - Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation - GlobeNewsWire
- 15 days ago - Apollomics, Inc. Company Operational Continuity Update - GlobeNewsWire
- 7 months ago - Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - GlobeNewsWire
- 7 months ago - Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewsWire
- 11 months ago - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 11 months ago - Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 1 year ago - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 1 year ago - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewsWire